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ABSTRACT 
RATIONALE: Liquid Chromatography-Mass Spectrometry (LC-MS)-based proteomics 
for absolute protein quantification has been increasingly utilized in both basic and clinical 
research. There is a great need to overcome some major hurdles of current absolute 
protein quantification methods, such as significant inter-assay variability and high cost 
associated with the preparation of purified stable isotope-labeled peptide/protein 
standards. 
METHODS: We developed a novel targeted absolute protein quantification method, 
named TAQSI, utilizing full-length isotope-labeled protein internal standards generated 
from SILAC (stable isotope labeling by amino acid in cell culture) and unlabeled full-
length protein calibrators. This approach was applied to absolute quantification of 
carboxylesterase 1 (CES1), the primary human hepatic hydrolase, in a large set of human 
liver samples. Absolute CES1 quantities were derived from the standard calibration 
curves established from unlabeled CES1 protein calibrators and the isotope-labeled CES1 
internal standards obtained from SILAC HepG2 cells.   
RESULTS: The TAQSI assay was found to be accurate, precise, reproducible, and cost 
effective. Importantly, protein quantification was not affected by various protein 
extraction and digestion protocols, and measurement errors associated with 
nonsynonymous variants can be readily identified and avoided. Furthermore, the TAQSI 
approach significantly simplifies the procedure of identifying the best performance 
surrogate peptides.  
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CONCLUSIONS: TAQSI assay can be widely used for targeted absolute protein 
quantification in various biomedical research and clinical practice settings. 
 
Keywords: absolute quantitative proteomics; LC-MS/MS; MRM; SILAC; HepG2 cells; 
human liver; carboxylesterase 1; protein expression  
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INTRODUCTION 
Mass spectrometry (MS)-based absolute targeted protein quantification is being 
increasingly adopted in proteomics research, and has proven its utility in both basic 
research and clinical biomarker discovery and validation. Several absolute quantitative 
proteomics approaches have been developed utilizing different stable isotope-labeled 
internal standards (IS), such as synthetic peptides (AQUA),[1-3] quantification 
concatemers (QconCATs),[4, 5] full-length protein standards (PSAQ) and absolute SILAC 
(stable isotope labeling by amino acid in cell culture).[6-8] A combination of isotope-
labeling IS-based approaches with modern MS/MS technologies, mainly multiple 
reaction monitoring (MRM), permits high accuracy and precision in absolute protein 
quantification.  
To perform AQUA, the most commonly used absolute protein quantification method, 
isotopically labeled synthetic peptides are added to digested protein samples as the IS, 
followed by peptide extraction and MS analysis. Protein quantity is determined according 
to the ratio of peak intensities of unlabeled natural peptides to their heavy isotope-labeled 
counterparts. AQUA is based on the assumptions that 1) all targeted proteins are fully 
recovered after protein extraction; 2) the selected reference peptides are fully digested 
from the proteins of interest and remain intact during enzymatic digestion.[9, 10] However, 
these assumptions have never been fully verified for most proteins/peptides.[6, 11] 
Additionally, synthesis and purification of isotope labeling peptides is often expensive.  
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Another commonly used absolute protein quantification method is the QconCATs.[4, 5] 
QconCATs are artificial proteins made of a number of concatenated surrogate peptides 
for various analyte proteins. Isotope-labeled QconCATs are obtained via the expression 
of artificial QconCATs genes in cells cultured in a heavy isotope enriched medium. 
QconCATs are added to protein samples before digestion, and the digested concatenated 
peptides serve as IS for different proteins. A major pitfall with this approach is that 
protein extraction and digestion efficiencies could vary significantly between QconCATs 
and native proteins due to different amino acid compositions.[7, 12]  
Protein standards for absolute quantification (PSAQ) and absolute SILAC are an 
alternative approach to the AQUA and QconCATs. PSAQ and absolute SILAC involve 
biosynthesis and purification of stable isotope-labeled analyte proteins and the addition of 
a known quantity of labeled proteins to samples before extraction and digestion.[6, 7] 
PSAQ and absolute SILAC can overcome some drawbacks of AQUA and QconCATs, 
such as the variations associated with protein extraction and digestion. However, PSAQ 
and absolute SILAC are generally low-throughput assays, and each isotope-labeled 
protein standard has to be generated and purified individually, which is very labor 
intensive and expensive.  
In addition to the stable isotope labeling-based methods, so-called “label-free” absolute 
quantification methods have been developed using unlabeled proteins as external 
standard.[13, 14] However, this approach is generally considered unfavorable in terms of 
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accuracy and precision when compared with the methods employing isotopically labeled 
IS.   
In view of the aforementioned limitations of current assays, in the present study, we 
developed a novel targeted absolute quantitative proteomics approach that employs 
SILAC IS and unlabeled full-length protein calibrators. This approach, named TAQSI, 
offers several advantages, such as lower cost and improved robustness and accuracy, over 
current existing methods. This method was successfully applied to a proof-of-concept 
study to quantify absolute expressions of carboxylesterase 1 (CES1) in human livers.    
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EXPERIMENTAL 
Materials 
Urea, dl-dithiothreitol (DTT), trifluoroacetic acid (TFA), and acetonitrile were purchased 
from Fisher Scientific Co. (Pittsburgh, PA). Iodoacetamide (IAA) was the product of 
Acros Organics (Morris Plains, NJ). TPCK-treated trypsin was obtained from 
Worthington Biochemical Corporation (Freehold, NJ). Water Osis HLB columns were 
from Waters Corporation (Milford, MA). Recombinant CES1 (purity > 95%) was the 
product of R&D system (Minneapolis, MN). Dulbecco’s Modified Eagle Medium 
(DMEM), fetal bovine serum (FBS), and 100 × antibiotics mixture containing penicillin 
(100 IU/ml) and streptomycin (100 µg/ml) were the products of Invitrogen (Carlsbad, 
CA). Trypsin-EDTA (0.25%) and SILAC Protein Quantitation Kit-DMEM containing 
SILAC DMEM (deficient in arginine and lysine), 13C6 l-lysine-2HCl, 13C615N4 l-arginine-
HCl, and dialyzed FBS were obtained from Thermo Scientific (Waltham, MA). Sterile 
syringe filters with 0.2μm sterile cellulose acetate membranes were purchased from 
VWR international Inc. (Bridgeport, NJ). HepG2 cells were purchased from ATCC (HB-
8065TM, Manassas, VA). A total of 102 individual normal human liver samples were 
randomly selected from 535 biobanked samples. These liver samples were obtained from 
several sources including the University of Minnesota Liver Tissue Cell Distribution 
System, Cooperative Human Tissue Network (CHTN), and XenoTech LLC (Lenexa, 
KS). The donors consisted of 92 Caucasians, 6 African-Americans, 2 Hispanics, and 2 
This article is protected by copyright. All rights reserved.
classified as others, with 46 males and 56 females. The donor ages ranged from 22 to 81 
years old. 
Cell culture and SILAC labeling 
Human hepatocellular carcinoma cell line HepG2, which exhibits similar gene expression 
pattern of human livers, was utilized to generate stable isotope labeling proteins. HepG2 
cells were initially cultured in DMEM containing 10% FBS, 100 IU/ml penicillin and 100 
µg/ml streptomycin at 37 ℃ under 5% CO2 and 95% humidity. The SILAC culture 
medium consisted of SILAC DMEM supplemented with 0.1 mg/ml of 13C6 l-lysine-2HCl 
and 0.1 mg/ml 13C615N4 l-arginine-HCl, 10% dialyzed FBS, 100 IU/ml of penicillin and 
100 µg/ml streptomycin. To obtain isotope-labeled cell culture, HepG2 cells were 
cultured in SILAC DMEM, and the medium was replaced every 3 days. Cells were 
subcultured when reaching 90% confluency. MS analysis showed that the incorporation 
rate of isotope-labeled arginine and lysine was more than 99% in the cell S9 fractions 
after cells were cultured in SILAC medium for 5 generations or more. Thus, only the 
HepG2 cells with SILAC culture ≥ 5 passages were utilized in the study. To avoid 
potential variability in protein expression between different batches of cell culture, all 
SILAC S9 fractions were pooled, and subsequently used throughout the entire 
experiment.   
Samples preparation  
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Individual human liver S9 fractions (HLS9) were prepared from about 200 mg frozen 
liver tissues. The liver tissues were cut into small pieces (1×1×1 mm) and homogenized 
in 0.5ml ice-cold phosphate buffer saline (PBS) in 1.5 ml microcentrifuge tubes using a 
microcentrifuge pestle (VWR International LLC, Chicago, IL). The homogenates were 
centrifuged at 9000 ×g at 4 °C for 20 min. Following the centrifugation, the top layer 
containing fats was carefully removed, and the remaining samples were centrifuged again 
at 9000 ×g at 4 °C for 20 min to remove the remaining fats. The resulting supernatants 
(S9 fractions) were collected and diluted to 2 mg/ml in PBS.  HepG2 cell S9 fractions 
were prepared based on our previously published method.[15] Protein concentrations of 
human liver and HepG2 S9 fractions were determined using Pierce BCA protein 
quantification assay. An aliquot of 20 μl of HLS9 from each of the 102 samples prepared 
were mixed to make the pooled HLS9 sample. All samples were stored at -80 °C until 
use.  
Protein aliquots of 20 μg HLS9 and 40 μg SILAC HepG2 cell S9 fractions (IS) were 
mixed in Eppendorf Protein LoBind tubes, followed by addition of 10-fold volume of 
acetonitrile. The mixtures were briefly vortexed and then centrifuged at 17000 ×g for 10 
min at 4℃. The supernatants were discarded, and the precipitated proteins were air dried 
for 5 min at room temperature. The dried proteins were re-suspended in 100 μl of freshly 
prepared 4 mM DTT/8 M urea solution, and incubated at 37 ℃ for 45 min. Following the 
incubation, samples were cooled to room temperature, and then alkylated by incubation 
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with 100 μl of freshly prepared 20 mM IAA solution at room temperature for 30 min in 
dark. After alkylation, 800 μl water was added to dilute urea concentration to 0.8 M. 
Samples were then digested by trypsin at an enzyme/protein ratio of 1:500 in an 
incubation shaker at 200 rpm at 37℃ for 16 h. The digestion was terminated by the 
addition of 1 μl TFA. Digested peptides were extracted using Waters Oasis HLB columns 
according to the manufacture’s instructions. Extracted peptides were dried in a Speed 
Vac SPD1010 (Thermo Scientific, Hudson, NH), and reconstituted in 80 μl of 50% 
acetonitrile. The peptide solutions were centrifuged at 17,000 ×g for 10 min at 4°C, and 
the supernatant was collected for LC-MS/MS analysis.  
Unlabeled purified recombinant full-length CES1 protein was obtained from R&D 
system (Minneapolis, MN), and was utilized as a calibrator to prepare the calibration 
solutions for the quantification of CES1 expression in human livers. The CES1 
calibrators were 0.59, 1.18, 2.36, 4.73 and 11.82 pmol, which cover normal range of 
CES1 expressions in 20 μg proteins of human livers. Quality control (QC) samples were 
also prepared from the recombinant CES1 with absolute quantities of 1.18, 2.36 and 4.73 
pmol. Additionally, a pooled HLS9 sample (12 μg protein) was included in each run to 
further evaluate the between-run variability. Calibrators and QC samples were processed 
in parallel with liver samples using the aforementioned sample preparation protocol. 
Figure 1 is the illustration of the workflow of the TAQSI assay and its comparison to 
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other absolute protein quantification methods including AQUA, QconCATs, PSAQ and 
absolute SILAC. 
To evaluate the impact of digestion completion on protein quantification, we quantified 
CES1 after 1, 2, 4, 8, 12, 16, 24 h trypsin digestion using the same sample preparation 
method described above.  
LC-MS/MS analysis  
The workflow of LC-MS/MS analysis of absolute CES1 expression was established with 
the assistance of the Skyline software (University of Washington, Seattle, WA). A list of 
26 candidate peptides were generated based on the MS/MS spectrum currently available 
in NIST and human ISB Plasma spectral libraries (Supplemental Table 1). The peptides 
containing any nonsynonymous variants with a minor allele frequency > 0.1% were 
excluded, resulting in four peptides being removed from the original list. A table 
containing the top three most intensive precursor-product ion transitions of each of the 
remaining 22 peptides and the corresponding MS/MS instrumental parameters (e.g. dwell 
time, ionspray voltage, declustering potential, collision energy) was generated from 
Skyline, and was integrated into the LC-MS/MS method. The method was applied to the 
analysis of CES1 quantities in three pooled HLS9 samples. A total of 6 unique CES1 
peptides that exhibited the highest intensity of MS/MS spectra were targeted in the final 
method (Supplemental Table 2).  
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The LC-MS/MS analysis was performed on a triple quadruple mass spectrometer (API 
4000 QTRAP®, AB SCIEX, Concord, ON) coupled with a Shimadzu Prominence HPLC 
system (Shimadzu Corporation, Kyoto Japan). Analytes were separated on an Agilent 
ZORBAX 300SB-C18 column (5 µM, 150×2.1mm, Agilent Technologies, Santa Clara, 
CA) set at 40°C. The mobile phase consisted of acetonitrile (phase A) and water (phase 
B), both containing 0.1% formic acid (v/v), and was delivered at a flow rate of 0.2 
ml/min. A gradient elution was applied for the separation with the following time 
program: phase A was set at 5% from 0 to 1 min and increased to 37% from 1 to 20 min, 
and further increased to 100% from 20 to 25 min, and maintained 100% from 25 to 35 
min, then returned to 5% from 35 to 36 min, and maintained at 5% to the end of elution 
(40 min). The MS was operated in positive electrospray using a Turbolon Spray ion 
source.  
Digested bovine serum albumin (BSA) was utilized to generate the retention time 
predictor for the estimation of retention times of CES1 peptides. Standard curves were 
established based on the peak area ratios of the light (unlabeled) peptides from the 
recombinant CES1 to the heavy (isotope-labeled) peptides from the SILAC HepG2 S9 
fractions. Assay accuracy and precision were assessed by analyzing the four QC samples 
in each run.   
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RESULTS 
Consistency of protein quantification among the six reference peptides 
We determined absolute CES1 quantities in the three QCs and pooled HLS9 samples 
using the six selected CES1 signature peptides. No significant interference peaks were 
observed for any of the peptides (Figure 2). The quantifications were consistent across 
the six peptides with the relative standard deviation (RSD) of 2.0%, 2.5%, 2.0%, and 
2.3% for 1.18, 2.36, 4.73 pmol QCs, and pooled human liver S9, respectively (Figure 3). 
The results suggest that the variability of CES1 quantification among the different 
signature peptides is very small, and any of the six surrogate peptides could be used to 
reliably quantify CES1 expression in human livers.  
Linearity, accuracy, and precision 
The standard calibration curves, established by plotting peptide quantity versus the peak 
area ratio of unlabeled-to-isotope labeled peptides, were found to be linear within the 
tested range (0.59 – 11.82 pmol) for all six peptides (Supplemental Table 3). This range 
was anticipated to bracket possible CES1 quantities in 20 µg protein of HLS9 samples. 
The correlation coefficients of all six peptides were greater than 0.9999 under our 
experimental conditions (Supplemental Table 3). The precision and accuracy of the 
assay were determined utilizing the three QC samples (1.18, 2.36, 4.73 pmol). As shown 
in Table 1, the inter- and intra-day precision measured as RSD were equal or less than 
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9.0% and 5.5%, respectively. The inter- and intra-day accuracy were within the ranges of 
96.1%-102.2% and 94.6%-106.1%, respectively. Pooled HLS9 samples with 20 µg of 
total proteins were included in each run to serve as an additional QC. The between-run 
RSDs of the pooled HLS9 sample were between 0.7% and 4.4% for the six selected 
peptides.  
Digestion time 
To evaluate the effect of digestion completion on CES1 protein quantitation, a mixture 
containing 20 µg protein of pooled HLS9 samples and 40 µg protein of SILAC HepG2 
cell S9 fractions (IS) was digested by trypsin at an enzyme/protein ratio of 1:500 for 1, 2, 
4, 8, 12, 16, and 24 h. The intensity of MS/MS spectra of both the six unlabeled surrogate 
CES1 peptides and their isotope-labeled counterparts were increased from 1 to 8 h 
following digestion, and reached a plateau after 8 h. However, the ratios of the light to 
heavy peptides that we used for CES1 quantitation remained consistent during the whole 
period time of digestion, indicating that incomplete digestion should not affect protein 
quantitation results of the TAQSI method (Figure 4).  
LC-MS/MS quantification of CES1 protein in human liver samples 
CES1 expressions and activities vary significantly among individual human livers. We 
applied the newly developed TAQSI assay to quantifying absolute CES1 expression in 
102 individual human liver samples. CES1 expression was found to vary significantly 
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among those liver samples, ranging from 42.0 ± 2.3 to 477.9 ± 21.9 pmol/mg protein. 
The mean expression level was 176.08 ± 75.6 pmol/mg protein (10.0 ± 4.2 μg/mg 
protein), which is approximately 1% of total proteins expressed in human liver. To 
evaluate the reproducibility of the assay, a total of 24 samples were analyzed for CES1 
expression by two independent experiments. The RSD was found to range from 0.1% to 
3.8% between the two runs among those samples, indicating that the method is highly 
reproducible (Figure 5). 
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DISCUSSION 
In the present study, we established a novel LC-MS/MS approach for absolute 
quantification of targeted proteins with very high accuracy and precision. Compared with 
current absolute protein quantification assays, our method is advantageous in the 
following three major aspects.  
Reducing inter-assay variability and improving accuracy and precision 
AQUA is the most commonly used method for absolute protein quantification, and has 
been adopted in many basic and clinical proteomics studies.[9, 16, 17] To perform AQUA, 
isotope-labeled synthetic peptide(s) are added to samples as IS after protein digestion. As 
a result, the isotope-labeled peptide IS(s) are not able to correct for systematic and 
accidental errors that may have occurred during protein extraction and enzymatic 
digestion. It is also noted that proteotypic peptide yields are often protein/peptide 
dependent, which makes it very difficult to establish a digestion protocol that is ideal for 
all targeted proteins. As shown in the Figure 4, different digestion protocols can 
significantly affect the yields of targeted peptides. Furthermore, the stability of peptides 
during digestion could introduce additional variability to the recovery of peptides. 
Consequently, protein quantification results could differ significantly when different 
isotope-labeled IS peptides or extraction and digestion protocols are utilized. For 
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instance, the use of different isotope-labeled IS peptides resulted in more than 7-fold 
differences of UGT1A4 quantification in the same human liver samples.[18]  
Distinct from AQUA, in which synthetic isotope-labeled peptides IS are used, our TAQSI 
approach employs full-length isotope-labeled native proteins obtained from SILAC as the 
IS. The full-length labeled proteins are added to the lysate of tissues or cells before 
protein extraction and digestion. Therefore, the variabilities introduced from protein 
extraction and digestion as well as other downstream procedures can be largely 
eliminated. Our study demonstrated that, even though peptide recoveries varied 
depending on the time of digestion, the unlabeled-to-labeled ratios of all six selected 
CES1 peptides remained consistent throughout the digestion process (Figure 4). Thus, 
the TAQSI method is robust in terms of being resistant to the inter-assay variability 
caused by imperfect protein extraction and/or digestion protocols and the selection of 
different surrogate peptides.      
Similar to our TAQSI approach, PSAQ and absolute SILAC assays can significantly 
reduce the variability associated with protein extraction and digestion.[6, 7, 9] However, 
each PSAQ and absolute SILAC isotope standards need to be individually generated from 
cell free systems or SILAC, and further purification and quantification are required 
before the proteins can be utilized as the standards for protein quantification. The whole 
procedure of PSAQ and absolute SILAC standard preparation is often very expensive and 
time consuming. Full-Length Expressed Stable Isotope-labeled Proteins for 
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Quantification (FLEXIQuant) is a further development of PSAQ assay,[19] in which 
isotope–labeled protein standards tagged with a FLEX-peptide are generated from cell 
culture. Relative to PSAQ, the major advantage of FLEXIQuant is that the FLEX-peptide 
allows for absolute protein quantification without the need for the purification of the 
isotope-labeled FLEXIQuant IS. However, each FLEXiQuant standard has to be 
generated individually through customized expression constructs, which hinders the 
applicability of this assay in simultaneous quantification of multiple proteins. With 
comparison to PSAQ, absolute SILAC and FLEXiQuant, our TAQSI method utilizes 
unpurified multiple isotope-labeled IS proteins simultaneously generated from SILAC. 
Additionally, unlabeled full-length proteins, which serve as the external standards for the 
construction of calibration curves, are often commercially available, or can be readily 
prepared in house through standard molecular biological assays. Thus, the TAQSI 
method appears to be an efficient and cost effective alternative approach of the 
established PSAQ and FLEXIQuant assays. 
Reducing measurement errors caused by nonsynonymous variants 
Measurement errors in protein quantification can occur when samples contain 
nonsynonymous variants that reside in the selected signature peptide(s). As a general 
principle, peptides containing high-frequency nonsynonymous variants should be avoided 
when selecting surrogate peptides for protein quantification. However, availability of 
suitable peptides for protein quantification is often limited due to that the selected 
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peptides also need to satisfy other criteria, such as specificity, MS/MS sensitivity, and 
digestion efficiency, etc. It is not uncommon that peptides with reported nonsynonymous 
variants are adopted as surrogate peptides for protein quantification. The TAQSI 
approach allows to apply multiple signature peptides to protein quantification without 
increasing overall costs and assay complexity. The data from our proof-of-concept study 
of absolute CES1 quantification demonstrated very consistent quantitative results across 
the different signature peptides (Figure 3). Missing peaks of an unlabeled peptide would 
indicate a homozygous nonsynonymous variant in the peptide whereas it would suggest 
the presence of a heterozygous nonsynonymous variant if the calculated protein quantity 
based on a selected peptide is approximately 50% of that determined from other reference 
peptides (Supplemental Figure 1). Thus, cross examination of the data derived from 
different peptides can not only enhance the assurance and reliability of quantification data 
but also allow to identify the peptide(s) containing nonsynonymous variants and exclude 
it from the final data analysis.   
Simplifying the selection of optimal performance proteotypic peptides 
Ideal reference peptides for protein quantification should meet several criteria, including 
1) be unique to targeted proteins; 2) generate good MS/MS responses; 3) be chemically 
stable; 4) be unlikely affected by genetic variants. Some bioinformatics tools have been 
developed to aid in signature peptides selection.[20, 21] However, it remains a challenging 
task to predict the best performance peptides as MS/MS profiles of a peptide can be 
This article is protected by copyright. All rights reserved.
affected by many experimental conditions, such as MS instrumentation and sample 
preparation methods. AQUA assays usually do not test all candidate peptides due to the 
high costs of obtaining synthetic isotope-labeled peptides. Therefore, the peptide(s) 
selected from limited candidate peptides might not be the best performance peptides for 
AQUA protein quantification. Our TAQSI method employs full-length unlabeled and 
labeled native proteins, which allows us to readily explore the performance of all digested 
peptides unbiasedly during method development. In the present proof-of-concept study, 
we evaluated a total of 22 CES1 candidate peptides and identified six peptides with the 
best performance in terms of MS/MS responses and chromatographic selectivity (Figure 
2).    
Limitations 
Several limitations have been recognized for the TAQSI assay. First of all, purified 
unlabeled whole length proteins, utilized as the calibrators to establish standard curve for 
absolute quantification, are associated with the added costs and efforts related to the 
purchase or preparation of those protein calibrators. Secondly, given that this method 
relies on SILAC internal standard, potential applications of this approach may be limited 
by the availability of SILAC culture medium. Although commercial SILAC kits currently 
available already contain those most commonly used medium such as DMEM and RPMI 
1640, it could be difficulty to obtain some less commonly used medium in SILAC form. 
Finally, the use of whole protein lysates of SILAC cells as the internal standard could 
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increase the complexity of protein samples and may enhance the background noise, 
which could pose a challenge to quantify the proteins with low abundance.   
CONCLUSIONS 
We have developed a novel LC-MS/MS-based MRM absolute targeted protein 
quantification method, named TAQSI, which is accurate, precise, reproducible, and cost 
effective relative to other existing methods. This approach has the potential to be widely 
used in the study of protein expression in various biomedical research settings and 
absolute quantification of protein therapeutics in pharmaceutical industry. Additionally, 
the reproducibility of the TAQSI makes it a preferred tool for the discovery and 
validation of clinical protein biomarkers for quantitative proteomics-based diagnostics 
and precision medicine.  
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Table 1. Intra-day and inter-day assay precision and accuracy of three QC samples of the 
six unique peptides for CES1 quantification. 




Accuracy (%) Precision (%) Accuracy (%) Precision (%) 
AISESGVALTSVLVK 
     1.18 101.9 2.4 
 
96.1 5.5 
2.36 95.1 3.9 
 
98.9 3.3 




     1.18 100.5 2.8 
 
97.8 1.1 
2.36 96.8 3.2 
 
98.2 4.3 




     1.18 106.1 2.4 
 
100.0 9.0 
2.36 104.2 4.1 
 
100.2 4.1 




     1.18 97.6 4.1 
 
98.1 5.7 
2.36 94.6 1.8 
 
96.8 5.0 




     1.18 95.8 4.3 
 
98.7 6.0 
2.36 98.4 4.8 
 
101.2 4.7 




     1.18 99.4 5.5 
 
99.7 3.2 
2.36 100.4 2.7 
 
100.8 3.5 
4.73 100.6 2.3 97.6 3.3 
 
*[CAM]: Cysteine was alkylated with iodoacetamide during sample preparation.  
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Figure Legends 
Figure 1. The workflow of the TAQSI assay and its comparison to other absolute protein 
quantification methods including AQUA, QconCATs, PSAQ and absolute SILAC. The 
TAQSI method employs a dilution series of unlabeled target proteins as calibrators and 
SILAC preparations containing target proteins as the internal standards (I.S.) to generate 
calibration curves for absolute protein quantification. Equal amount of SILAC I.S. is 
spiked in calibrators and unknown samples. The mixers are then processed according to 
the procedures detailed in the Methods section. Following LC-MS/MS analysis, absolute 
amounts of target proteins are determined by comparing the ratios of unlabeled-to-labeled 
signature peptides to the established calibration curves. The major differences between 
the PSAQ/Absolute SILAC and the TAQSI assays are that the PSAQ/Absolute SILAC 
methods require purified isotope-labeled I.S., and protein concentrations are calculated 
directly from the ratios of unlabeled-to-labeled peptides without using calibration curves. 
Unlike the PSAQ/Absolute SILAC and TAQSI assays in which full-length isotope-
labeled proteins I.S. are used, the QconCATs assay utilizes artificial proteins made of a 
number of concatenated surrogate peptides as the I.S.. For AQUA, the I.S. are 
isotopically labeled synthetic individual peptides. It should be noted that the I.S. of the 
PSAQ/Absolute SILAC, the TAQSI, and the QconCATs assays are added before sample 
processing while the AQUA I.S. are spiked after protein digestion. 
Figure 2. Representative LC-MS/MS chromatograms of the six selected unique CES1 
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peptides (A: AISESGVALTSVLVK, B: FLSLDLQGDPR, C: TAMSLLWK, D: 
SYPLVC[CAM]IAK, E: ELIPEATEK, F: FWANFAR) and their corresponding isotope-
labeled peptides. The data were obtained from the analysis of the mixture of pooled 
HLS9 samples and SILAC HepG2 S9 fractions.  
Figure 3. Absolute CES1 quantities in three QCs and pooled HLS9 samples determined 
using the six selected CES1 signature peptides. Nominal CES1 quantities in the low, 
medium, and high QC samples were 1.18, 2.36, 4.73 pmol, respectively. The pooled 
HLS9 sample contained 20 μg of total proteins. 
Figure 4. The impact of digestion time on the MS/MS intensities of the six unlabeled and 
isotope-labeled CES1 signature peptides as well as their ratios. The MS/MS peak 
intensities of both labeled and unlabeled peptides increased along with the time of 
digestion, and reached plateau after 8h tryptic digestion. However, the ratios of 
unlabeled-to-labeled peptides remained consistent throughout the period of digestion. 
Data are mean ± S.D. from three independent experiments. 
Figure 5. Absolute CES1 quantities (pmol/mg total protein) in 24 HLS9 samples. CES1 
expression was determined based on the averages of the CES1 quantities calculated from 
the six surrogate CES1 peptides. Data are presented as means from two independent 
studies with error bars representing S.D..   
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